X0609 4 2026-08-27 1 0001419041 Forte Biosciences, Inc. FBRX 0001339375 Riley Antony A false C/O FORTE BIOSCIENCES, INC. 3060 PEGASUS PARK DR., BLDG 6 DALLAS TX 75247 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2026-08-27 4 U 0 42600 D 0 D Stock Option (right to buy) 31 2026-08-27 4 D 0 421 D 2024-03-24 2030-03-29 Common Stock 421 0 D Stock Option (right to buy) 364.50 2026-08-27 4 D 0 2999 D 2024-03-23 2030-06-30 Common Stock 2999 0 D Stock Option (right to buy) 991.50 2026-08-27 4 D 0 1700 D 2025-04-09 2031-04-09 Common Stock 1700 0 D Stock Option (right to buy) 43 2026-08-27 4 D 0 2999 D 2026-01-17 2032-01-17 Common Stock 2999 0 D Stock Option (right to buy) 17.25 2026-08-27 4 D 0 14000 D 2034-03-21 Common Stock 14000 0 D Stock Option (right to buy) 7.54 2026-08-27 4 D 0 323000 D 2035-03-20 Common Stock 323000 0 D Stock Option (right to buy) 29.66 2026-08-27 4 D 0 90000 D 2036-01-12 Common Stock 90000 0 D Stock Option (right to buy) 17.15 2026-08-27 4 D 0 22000 D 2036-06-16 Common Stock 22000 0 D Restricted Stock Units 2026-08-27 4 D 0 750 D Common Stock 750 0 D Restricted Stock Units 2026-08-27 4 D 0 60000 D Common Stock 60000 0 D Restricted Stock Units 2026-08-27 4 D 0 2976 D Common Stock 2976 0 D Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact 2026-08-27